Kwality Pharma received the approval for Leuprorelin Acetate for injectable suspension as a site variation from Greece

Kwality Pharmaceuticals Limited ('KPL') has successfully filed and got the approval for Leuprorelin Acetate 11.25 mg vial powder and solvent for injectable suspension as a site variation in Greece, marking our entry into the European Markets.

Kwality Pharma will supply the first three validation batches in December and after complete Quality Control Analysis, will start regular supplies from January 2025 onwards.

This strategic CDMO arrangement is projected to generate around USD 3 million of yearly sales, with distribution set to begin in the 4th Quarter of this fiscal year. Furthermore, we have plans to add remaining strengths of the same in the product portfolio with the same buyer as well.

This marks a pivotal step in our company strategy to introduce our products in highly regulated markets.

Shares of Kwality Pharmaceuticals Ltd was last trading in BSE at Rs. 896.25 as compared to the previous close of Rs. 897.10. The total number of shares traded during the day was 9582 in over 337 trades.

The stock hit an intraday high of Rs. 919.00 and intraday low of 860.00. The net turnover during the day was Rs. 8616108.00.

Source : Equity Bulls

Keywords

KwalityPharmaceuticals INE552U01010 Approval LeuprorelinAcetate